

CANACCORD GENUITY GROWTH CONFERENCE PRESENTATION

PERTH, Australia and SAN FRANCISCO, California – 13 August 2024

PYC Therapeutics Limited (ASX:PYC) is pleased to provide a copy of the presentation that will be given by PYC's CEO, Dr Rohan Hockings, at the Canaccord Genuity Growth Conference in Boston, USA on 13 August 2024.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

For more information, visit pyctx.com, or follow us on [LinkedIn](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA

info@pyctx.com

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.20222232>

ersonal use only

Canaccord Growth Conference

PYC Therapeutics

August 2024



Disclaimer



The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) ['PYC']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by PYC Therapeutics and should not be relied upon as an independent source of information. Please contact PYC and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of

which are outside PYC's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and PYC's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by PYC. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.


An introduction to PYC Therapeutics

- PYC is a clinical-stage drug discovery and development company with operations in Australia and the US
- The company is an emerging leader in the field of precision RNA therapies for patients with genetic diseases caused by haploinsufficiency in the eye, kidney and CNS
- PYC is developing four first-in-class drug candidates in areas of severe unmet need for the tens of millions of patients worldwide affected by these diseases:
 - Retinitis Pigmentosa type 11 (RP11)
 - Autosomal Dominant Optic Atrophy (ADOA)
 - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
 - Phelan-McDermid Syndrome (PMS)
- PYC's novel therapeutics are based on a platform of oligonucleotides linked to a proprietary non-viral delivery technology

PYC has built a pipeline of first-in-class drug candidates with disease-modifying potential




Personal use only



¹ Based on management's latest estimates accurate as at 4 July 2024 and subject to successful realisation of developmental milestones in each program as well as satisfaction of regulatory requirements and subject to all other risks customary to an early-clinical stage biotechnology company developing novel drug candidates
² See references in Company presentation of 14 March 2024 for source material on prevalence by indication
³ PYC 96.2% ownership of VP-001 (3.8% ownership by Lions Eye Institute, Australia) and 100% ownership of all other pipeline programs

Each asset in the pipeline is a high-propensity and differentiated program that aims to maximise patient-impact

PYC's strategy is built on 4 pillars



1. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank. doi: <https://doi.org/10.1101/2020.11.02.20222232>

2. <https://endpts.com/roche-launches-institute-of-human-biology-in-search-of-predictive-models/>

3. Refer ASX announcement 3 October 2022 for PYC OTS Poster Presentation


1. Drugs targeting single gene disorders are 5x more likely to succeed in clinical development¹

“Genetics is so powerful and it provides you with a level of validation around the disease target that is incomparable in drug development. There are so many data points that show that drug discovery programs that are grounded in genetics have an outsized likelihood of being successful at the end of the day.”

John Maraganore, Alnylam

2. PYC validates all pipeline candidates in patient-derived models before it enters clinical development

1. PYC can create a patient-derived retina




This enables it to determine whether its drug candidate can:




- i. Address the underlying cause of the disease (quantitatively); and
- ii. Rescue the disease phenotype (functionally/morphologically)



Retinitis Pigmentosa type 11 (RP11) untreated



RP11 treated with VP-001




3. The unique suitability of RNA therapies for diseases caused by haploinsufficiency is now being recognised



nature reviews drug discovery

<https://doi.org/10.1038/s41573-023-00704-7>

Review article

 Check for updates

Amplifying gene expression with RNA-targeted therapeutics

Olga Khorkova^{1,2}, Jack Stahl^{2,3}, Aswathy Joji^{2,4}, Claude-Henry Volmar^{2,3} & Claes Wahlestedt^{2,3,4}  

Abstract

Many diseases are caused by insufficient expression of mutated genes and would benefit from increased expression of the corresponding protein. However, in drug development, it has been historically easier to develop drugs with inhibitory or antagonistic effects. Protein replacement and gene therapy can achieve the goal of increased protein expression but have limitations. Recent discoveries of the extensive regulatory networks formed by non-coding RNAs offer alternative targets and strategies to amplify the production of a specific protein.

Sections

Introduction

Biology of protein upregulation

NBTs for protein upregulation

Advantages and challenges for NBTs


Conclusions and outlook

“Catalysed by... a few monumental clinical successes, this burgeoning drug class is rapidly expanding and redefining the meaning of a druggable target”


4. PYC's precision therapy pipeline has been built on its proprietary non-viral drug delivery technology

PYC's non-viral drug delivery technology achieves ~100x the potency of the 'naked' RNA drug *in vivo*¹


1. PYC combines existing RNA drug design technology with its proprietary delivery platform to create potent and precise RNA drugs



2. PYC's delivery platform is used to assist the RNA drug reach its target inside the target cell



3. PYC's dual-function RNA drug achieves 100x the potency of the 'naked' RNA drug *in vivo*



PYC's PPMO (L) delivers more drug throughout the retina than an equivalent dose 2'MOE 'naked' oligo (R) – pink dots indicate drug in tissue¹

PYC has applied this enhanced potency in the context of serious diseases where no treatments are available

1. Refer ASX announcement for OTS poster presentation 3 October 2022

The integration of these 4 strategic pillars sets PYC up for clinical success in H2 2024

Pre-clinical



RP11 Patient-derived models



Safety and efficacy¹



Non-human primate



Safety and high drug concentration in target tissue²

Clinical



RP11 Patient



Safety³



RP11 Patient



Early efficacy⁴



RP11 Patient



Clinical proof of concept

PYC will generate human efficacy data across two concurrent clinical trials in its RP11 program in H2 2024⁵

Personal use only

¹ See ASX announcement of 7 October 2020, 16 December 2020 and 6 May 2024

² See ASX announcement of 10 May 2022 and 7 November 2022

³ See ASX announcement of 1 July 2024


⁴ See ASX announcement of 6 May 2024 and 5 August 2024

⁵ Based on management's latest estimates accurate as at 4 July 2024 and subject to successful realisation of developmental milestones in each program as well as satisfaction of regulatory requirements and subject to all other risks customary to an early-clinical stage biotechnology company developing novel drug candidates


The initial results in patients are encouraging – multiple patients have improved visual function after a single dose

Post single 30 µg treatment with PYC's drug candidate


Baseline




Week 4



Week 8



Week 16



Multiple patients in PYC's ongoing Single Ascending Dose study have improved visual function after a single dose of PYC's investigational drug candidate for a progressive and irreversible blinding eye disease:

- Enhanced whole grid retinal sensitivity;
- Enhanced sensitivity of functional transition points; and
- A decreased number of scotomas¹.

These results have been achieved in the absence of any adverse safety signals¹

- PYC's drug candidate benefits from a patient-preferred route of administration with a long dosing interval
- There have been no Treatment Emergent Serious Adverse Events in any patient observed to date¹
- There were no Treatment Emergent Adverse Events of any nature in the highest dose cohort in the Single Ascending Dose study¹

PYC's Retinitis Pigmentosa Type 11 program has the potential to be the first approved therapy in this indication¹

Degenerative sight of an RP11 patient


6 YEARS OLD



26 YEARS OLD



46 YEARS OLD



Retinitis Pigmentosa (RP)^{2,3}


- A severe and progressive blinding eye disease that begins in childhood
- Affects 1 in every 3,500 people (RP11 accounts for ~3% of RP)
- Patients experience night blindness followed by tunnel vision and ultimately legal blindness
- There are no treatments available for patients with RP type 11 nor are there any in clinical development

1. Subject to the risks and uncertainties described in the Company's ASX disclosures of 14 March 2024
2. Daiger S et al. 'Genes and Mutations Causing Autosomal Dominant Retinitis Pigmentosa' Cold Spring Harb. Perspect. Med. 5 (2014)
3. Ellingford J et al. 'Molecular findings from 537 individuals with inherited retinal disease' J Med Genet 53, 761-776 (2016)

This program is the first of three human efficacy read-outs anticipated within the next 18 months



PYC's path to market is staged with human data read-outs for first-in-class drugs with disease-modifying potential¹



1. Based on management forecasts as at 4 July 2024 and subject to the risks set out in the company's ASX disclosures of 14 March 2024